#USA #Middleton #Leo Cancer Care #Catalio Capital #Upright Radiotherapy

Leo Cancer Care Secures $40 Million in Funding

In a significant boost for healthcare innovation, Leo Cancer Care has successfully raised approximately $40 million from a funding round led by Catalio Capital Management. This funding marks a crucial step towards expanding the reach of its cutting-edge upright radiotherapy solutions, aimed at improving patient outcomes in the fight against cancer.

Based in Middleton, Wisconsin, Leo Cancer Care specializes in developing unique radiotherapy devices that allow patients to receive treatment while standing or sitting in a natural position. This approach is designed to enhance comfort, streamline clinical workflows, and ultimately broaden access to sophisticated cancer therapies around the world.

Co-founder and CEO Stephen Towe expressed enthusiasm about the involvement of Catalio Capital, stating, "The trust and support of new and returning investors highlight the growing recognition of upright radiotherapy's potential to improve patient experiences and expand access to advanced treatments globally." This sentiment is echoed by Dr. Nicholas von Guionneau from Catalio, who has joined Leo Cancer Care's board as an Observer. Dr. Guionneau emphasized the unique technology platform that Leo Cancer Care has developed, which is centered around the novel idea of upright patient positioning. He remarked, "These innovations unlock a pipeline of pioneering therapeutic and diagnostic products, promising a substantial improvement in patient care."

Leo Cancer Care's flagship product, Marie, named after the renowned physicist Marie Curie, represents a groundbreaking advancement in the field of radiotherapy. This upright positioning system integrates a CT scanner specifically designed for proton therapy, significantly simplifying the traditional therapeutic process and making it more accessible to patients. By eliminating the need for gantry rotation through patient rotation, Marie reduces both the complexity and cost of treatments. Importantly, it aims to cater to a patient demographic that often finds traditional treatment methods challenging.

With recent FDA clearance under its belt, Marie has already piqued the interest of numerous leading cancer centers across the United States, with the first patient treatments expected to commence later in 2025. Adding to the anticipation, Leo Cancer Care plans to unveil a new photon therapy product tailored for upright treatments at the upcoming ASTRO conference, highlighting the company's commitment to innovation in radiotherapy.

Leo Cancer Care's mission is clear: to redefine the experience of radiation oncology by reintroducing upright treatment protocols and enhancing patient comfort. By focusing on innovative imaging technologies and patient-centric solutions, the company aspires to challenge traditional practices and improve the quality of care delivered globally.

\---

About Leo Cancer Care

Founded on the belief that patients deserve better treatment experiences, Leo Cancer Care is revolutionizing the field of radiation therapy. The company collaborates with prominent healthcare institutions and industry partners to innovate solutions that facilitate more natural treatment settings. They aim to lead the way in harnessing upright positioning and advanced imaging technologies, particularly for those seeking cutting-edge cancer care solutions.

About Catalio Capital Management

Catalio Capital Management, based in New York, is dedicated to healthcare investing, focusing on innovative companies at various stages of development. By collaborating with esteemed scientists and entrepreneurs, Catalio supports transformative health solutions seeking to make a difference in patient care worldwide. Their commitment to healthcare aligns seamlessly with Leo Cancer Care's mission, promising a fruitful partnership aimed at expanding the horizons of cancer treatment.